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Single-chain antibody fragments (scFv), consisting of two linked variable regions (VH and VL), 
are a versatile format for engineering and as potential antigen-specific therapeutics. Although the 
analogous format for T cell receptors (TCRs), consisting of two linked V regions (Vα and Vβ; 
referred to here as scTv), could provide similar opportunities, all wild-type scTv proteins 
examined to date are unstable. This obstacle has prevented scTv fragments from being widely 
used for engineering or therapeutics. To further explore whether some stable human scTv 
fragments could be expressed, we used a yeast system in which display of properly folded 
domains correlates with ability to express the folded scTv in soluble form. We discovered that, 
unexpectedly, scTv fragments that contained the human Vα2 region (IMGT: TRAV12 family) 
were displayed and properly associated with different Vβ regions. Furthermore, a single 
polymorphic residue (Serα49) in the framework region conferred additional thermal stability. 
These stabilized Vα2-containing scTv fragments could be expressed at high levels in Escherichia 
coli, and used to stain target cells that expressed the specific pep-HLA-A2 complexes. Thus, the 
scTv fragments can serve as a platform for engineering TCRs with diverse specificities, and 
possibly for therapeutic or diagnostic applications. 
Keywords: directed evolution, peptide-MHC, single-chain, T cell receptors, yeast display 
 
Introduction 
T cell receptors (TCRs) mediate recognition of a foreign or self-peptide presented in the context 
of a self major histocompatibility (MHC) complex protein (reviewed in Rudolph et al., 2006). 
During development, T cells that express the highest affinity receptors are deleted in the thymus 
in a process called negative selection. Survival of the T cell, however, depends on a minimal 
affinity for self-MHC (positive selection), assuring that T cell recognition is MHC-restricted 
(reviewed in Starr et al., 2003). After development, if recognition of peptide:MHC (pepMHC) is 
of sufficient affinity, the T cell becomes activated and secretes cytokines or causes lysis of the 
target cell. The affinity of TCR:pepMHC interactions is relatively low, with KD values in the 
range of 1–500 μM (Davis et al., 1998; van der Merwe and Davis, 2003; Stone et al., 2009). 
In recent years, in vitro engineering by yeast and phage display has yielded TCRs with >1000-
fold improvements in affinity for class I MHC ligands (Holler et al., 2000, 2003; Chlewicki et 
al., 2005; Li et al., 2005; Dunn et al., 2006; Varela-Rohena et al., 2008) and class II MHC 
ligands (Weber et al., 2005). To date, there have been only a few MHC-restricted human TCRs 
engineered for improved affinity by phage display (reviewed in Richman and Kranz, 2007). 
These receptors were engineered in a full-length TCR format (Li et al., 2005; Dunn et al., 2006; 
Varela-Rohena et al., 2008), with the addition of two non-native cysteines in each of the TCR 
constant domains to facilitate TCR heterodimer formation through an interchain disulfide bond 
(Boulter et al., 2003). The addition of this disulfide bond allows the TCR to be expressed on the 
surface of yeast (Richman et al., 2009) or phage (Boulter et al., 2003). 
Other affinity engineering efforts have focused on using a single-chain TCR (scTv) format, 
consisting of the variable domains of the TCR connected by a flexible linker (Vα–linker–Vβ or 
Vβ–linker–Vα; called scTv here to distinguish it from antibody scFv fragments, and from 
scTCRs that contain three domains, typically Vα, Vβ and Cβ; Chung et al., 1994; Plaksin et al., 
1997; Card et al., 2004). Although analogous to antibody fragments in many aspects, unlike 
antibody scFv, the scTv requires mutations to allow for stable expression of the variable domains 
in the absence of the constant domains (Richman et al., 2009). Previously, scTv fragments have 
been isolated by yeast display through random mutagenesis and subsequent selection with 
clonotypic antibodies to select for mutations that stabilize the scTv and allow for yeast surface 
expression and/or thermal stability (Kieke et al., 1999; Shusta et al., 2000; Weber et al., 2005). 
These stable scTv scaffolds were subsequently used for engineering receptors of enhanced 
affinity and for expression as stable, soluble scTv (Shusta et al., 1999; Holler et al., 2000; Weber 
et al., 2005). 
Like scFv fragments compared with the full antibody molecule, scTv fragments potentially 
afford significant advantages compared with the full-length TCR format for engineering, soluble 
protein expression and therapeutic potential. Higher surface levels of the scTv can be achieved 
relative to the full-length TCR in the yeast display system (Richman et al., 2009). This allows for 
more TCR molecules to be displayed on the surface of each yeast cell, and improved avidity 
effects in the detection of bound peptide-MHC multimers. In addition, the scTv is produced as a 
single polypeptide, which avoids the requirement for production of each TCR chain as a separate 
polypeptide. This can enable production of large quantities of scTv fragments in relatively short 
time in comparison to proteins expressed and refolded in the full-length format. Most 
importantly, the scTv has potential applications as therapeutic or diagnostic reagents in vivo 
similar to scFv fragments, e.g. as bispecific single-chain molecules (Bargou et al., 2008) or as 
immunotoxins (Wayne et al., 2010). The scTv has the added potential of improved tissue 
penetration because of the reduced size of the scTv relative to the full-length receptor. This is 
especially important in cases where the TCR is directed against a tumor antigen, where tumor 
stroma could be targeted to effectively destroy cancerous cells (Zhang et al., 2007, 2008; 
Thomas et al., 2009). 
Previous efforts to engineer scTvs were dependent on having probes available to assess folding 
of the TCR Vα and Vβ domains. In the well-characterized 2C (Kieke et al., 1999) and 3L.2 
(Weber et al., 2005) TCR systems, stabilized scTv fragments were identified by probing with 
clonotypic antibodies that recognized the conformation of the properly folded and associated Vα 
and Vβ domains. Because the wild-type affinity of these receptors for specific pepMHC is 
relatively low, pepMHC tetramers could not be used to detect properly folded, stabilized scTv 
fragments. It has been known for some time that expression of the extracellular regions of the 
TCR as soluble protein is often problematic (reviewed in Rudolph et al., 2006), and that the scTv 
format is typically unstable (Richman et al., 2009). The explanations for scTv instability are 
probably related to the long-standing observations that particular VH families are more stable as 
scFv than other VH families. Thus, the human VH3 family confers enhanced stability, but stability 
is influenced by framework residues and complementarity determining regions (CDRs) 
(Honegger et al., 2009). Efforts to understand the structural basis of these effects are important 
because various scFv fragments as bispecific proteins are currently in various phases of clinical 
testing (reviewed in Thakur and Lum, 2010), and the development of a single, highly stable 
human scFv platform for different antigen specificities would be desirable (Miller et al., 2010). 
To this end, scFv libraries with randomized residues in all six CDR loops have been produced to 
obtain antibodies with high affinity for various antigens (Rothe et al., 2008). 
In the current study, we explored whether human scTv fragments might also be developed using 
a single platform, allowing the natural antigens of the TCR, peptides bound to HLA products, to 
be targeted. We used in vitro engineered, high-affinity TCRs in a single-chain format to isolate 
the first human stabilized scTv fragments (Vβ–linker–Vα), and we determined various features 
of the scTv that allowed them to be expressed as stable proteins, both on the surface of yeast and 
in soluble form from Escherichia coli. High-affinity TCRs were used as templates for random 
mutagenesis (error-prone PCR), and stabilized scTv fragments were isolated by selection with 
soluble peptide:HLA-A2 tetramers. We describe the isolation of variants of two stabilized, 
human scTv fragments, the A6 scTv that is specific for a peptide derived from the human T cell 
lymphotrophic virus Tax protein (peptide: Tax11–19, LLFGYPVYV), and the 868 scTv that is 
specific for a peptide derived from the human immunodeficiency virus Gag protein (peptide: 
SL977–85, SLYNTVATL). Both of these TCRs used the same exceptionally stable Vα domain: 
Vα2 (IMGT: TRAV12 family), whereas other human scTv fragments that were not able to be 
displayed, contained other Vα regions. We also demonstrated that a single polymorphic residue 
at position 49 of the Vα2 controlled susceptibility to thermal denaturation and influenced the 
stability of the corresponding Vβ domain of the scTv. Furthermore, the two scTv fragments 
could be expressed in soluble form from E.coli and were capable of specifically recognizing their 
cognate peptides bound to HLA-A2 on antigen-presenting cells. 
 
Materials and methods 
Antibodies, peptide:HLA.A2 tetramers and flow cytometry 
Antibodies used to detect yeast surface expression included: anti-human Vβ5.2, clone 1C1 
(FisherThermo Scientific), anti-HA eptiope tag clone HA.11 (Covance), anti-human Cβ clone 
8A3 (Endogen/Pierce), anti-human Cα clone 3A8 (Endogen/Pierce), goat anti-mouse IgG F(ab′)2 
AlexaFluor 488 secondary antibody (Invitrogen), goat-anti-mouse IgG F(ab′)2 AlexaFluor 647 
secondary antibody (Invitrogen) and streptavidin-phycoerythrin (SA:PE, BD Pharmingen). 
Peptides that bind to HLA.A2 [Tax11–19: LLFGYPVYV, NYESO-Val157–165: SLLMWITNV, 
SL977–85 (HIV-Gag): SLYNTVATL and WT-1126–134: RMFPNAPYL] were synthesized by 
standard F-moc (N-(9-fluorenyl)methoxycarbonyl) chemistry at the Macromolecular Core 
Facility at Penn State University College of Medicine (Hershey, PA, USA). HLA.A2 heavy 
chain was produced as inclusion bodies and refolded in vitro with HLA.A2 binding peptides and 
human β-2 microglobulin as described (Garboczi et al., 1996a,b). The HLA.A2 heavy chain 
contains a biotinylation substrate sequence which allows for in vitro biotinylation (Avidity, BirA 
enzyme) and subsequently for the formation of streptavidin:phycoerythrin peptide/MHC 
tetramer. Tetramer and antibody staining of yeast cells was performed on ice for 45 min using 
∼1 × 106 cells. Cells were subsequently washed with 500 μl PBS/BSA (0.5%) and analyzed by 
flow cytometry with an Accuri C6 flow cytometer. 
  
Cloning and expression of single-chain and full-length TCR genes in yeast 
display vectors 
scTv fragments and VβCβ for full-length TCR constructs were expressed from yeast display 
plasmid pCT302 (Vβ–L–Vα scTvs) (Boder and Wittrup, 2000) or p315 (VβCβ)p315 generously 
provided by K. Dane Wittrup, MIT), which contain a galactose-inducible AGA2 fusion and 
allow for growth in Trp or Leu media, respectively. The full sequence of the AGA-2 fusions with 
scTv genes A6 and 868 (see below) is shown in Supplementary data, Fig. S1. VαCα for full-
length TCR constructs was expressed from pCT302-secreted, a galactose-inducible system that 
allows for growth in Trp media. Gene induction involved growth of transformed EBY100 yeast 
cells to stationary phase in selection media followed by transfer to galactose-containing media. 
The single-chain genes for TCRs were synthesized by Genscript (Piscataway, NJ, USA) with 
mutations originally isolated for improved affinity by phage display of full-length TCR with a 
non-native disulfide bond in the C regions (Boulter et al., 2003). The TCRs are specific for 
various peptides in the context of HLA.A2: the A6 mutant clone 134 (KD = 2.5 nM) specific for 
Tax from human T cell lymphotrophic virus (Li et al., 2005), the 1G4 mutant clone C49C50 (KD 
= 1.3 nM) specific for NYESO (Sami et al., 2007) and an 868 mutant clone (KD of at least 10 
nM) specific for human immunodeficiency virus Gag peptide SL9 (Varela-Rohena et al., 2008). 
For the 868 mutant, the most prevalent clone listed from CDR2β (YVRGEE, affinity mutations 
underlined) and CDR3α (CAVRGAHDYALN) was generated (Varela-Rohena et al., 2008) 
(sequences of clones and published affinities are provided in Supplementary data, Table S1 and 
Fig. S2). The scTv genes (Fig. 1) consisted of the variable domains attached by the linker region 
GSADDAKKDAAKKDGKS (as described in Soo Hoo et al., 1992; Weber et al., 2005). The 
scTv genes were introduced into the yeast display vector pCT302 using NheI and XhoI 
restriction sites. The DNA and protein sequences of the stabilized clones A6-X15 and 868-Z11 




Fig. 1  Yeast surface display of scTv variable fragments. (A) Schematic of scTv fusions for the 
human TCRs 1G4, A6 and 868, which recognize peptides NYESO, Tax and HIV-Gag (SL9) in 
the context of HLA.A2 (Li et al., 2005; Dunn et al., 2006; Varela-Rohena et al., 2008). (B) 
Yeast surface expression of scTv fusions was monitored for expression of N-terminal expression 
tag [hemagluttanin (HA), solid gray] with anti-HA antibody and goat anti-mouse IgG alexa 488 
secondary antibody, or secondary antibody only as a control (black line). The negative peak in 
each histogram is due to yeast that have lost plasmid, and serves as an internal control for each 
induced yeast sample. To assess display of properly folded scTv fusions, cells were incubated 
with pep:HLA.A2 streptavidin:phycoerythrin tetramers. Null tetramer staining histograms are 
shown (gray line) as a control, along with the cognate tetramers, as indicated (black, solid). 
 
For construction of full-length TCR constructs, V-region genes were introduced into human full-
length VαCα and VβCβ as described (Boulter et al., 2003; Richman et al., 2009). In brief, Vβ 
genes of 868 and A6 were introduced into the p315 plasmid as a fusion to AGA-2 by ligation 
into NheI and BglII restriction sites and a BglII site was introduced into the Cβ gene. Vα genes 
were introduced into NheI and BamHI sites, and a BamHI site was introduced into the Cα gene, 
and both were cloned into a pCT302 secretion plasmid. The full-length TCR constructs 
contained a non-native Cys in each constant domain (α: Thr48Cys, β: Ser57Cys) to facilitate the 
formation of a disulfide bond (Boulter et al., 2003). C region cysteine residues that normally 
participate in an interchain disulfide bond in the stalk region were replaced with a stop codon and 
the Cβ cysteine at position 71 was mutated to a serine (Cβ: Cys71Ser). 
Construction, display and selection of mutated scTv yeast display libraries 
Error-prone PCR was used to generate random mutations, as described previously (Richman et 
al., 2009). PCR products were electroporated along with NheI and XhoI digested vector into 
yeast strain EBY100 to generate libraries by homologous recombination. Random mutational 
libraries of the A6, 868 and 1G4 scTv genes were induced in galactose-containing media (SG-
CAA) for 48 h, washed with 500 μl 0.5% PBS/BSA and stained with corresponding pep:MHC 
SA:PE tetramers (100 nM). Cells were washed (5 ml, 0.5% PBS/BSA), and the most fluorescent 
cells were selected using either a MoFlo (Cytomation) or a FACS Aria (BD Bioscience) high-
speed sorter. In some cases, libraries were subjected to additional rounds of thermal stability 
sorting whereby yeast cells were incubated at higher temperatures (A6: 42°C for 45 min, 868: 
40°C for 30 min) prior to staining. 
Cloning of single-site or multiple-site scTv mutants 
The PheVα49Ser mutation was introduced using Quikchange Lightning Kit (Stratagene, Agilent 
Technologies) with forward primer: 5′ 
GGTAAATCTCCAGAATTGATCATGTCCATCTACTCTAATGGTGACAAAGAAG 3′ and 
reverse complement primer: 5′ 
CTTCTTTGTCACCATTAGAGTAGATGGACATGATCAATTCTGGAGATTTACC 3′. The 
868 scTv with CDR2β (Sequence: YYEEEE) and CDR3α (Sequence: CAVRTNSGYALNFG) 
wild-type residues was synthesized by Genscript. The high-affinity mutations for each CDR 
were introduced into this template by splicing by overlap extension PCR (Warrens et al., 1997). 
Expression in E.coli, folding and biotinylation of soluble scTv fragments 
The 868-Z11 and A6-X15 scTv mutants were introduced into the pET28a expression vector 
using NcoI and EcorI (868-Z11, forward primer: 
5′TATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCG
CGGCAGCGAAGCTGGTGTTACTCAATCTCC 3′ 868-Z11, reverse primer: 
AAATGAATTCTTAAATATGTGGAGTAACCCAAAAAGAAGTACC). Plasmids were 
transformed into the BL21 cell line, and after culture and gene induction, cells were passed 
through a microfluidizer (Microfluidics Corporation, Newton, MA, USA) and inclusion bodies 
were isolated and protein was purified as described (Garcia et al., 2001). scTv proteins were 
folded from inclusion bodies and purified with Ni agarose resin (Qiagen, Valencia, CA) followed 
by gel filtration (Superdex 200). Folded proteins were biotinylated using N-hydroxysuccinimide 
(NHS) biotin ester (EZ-Link Sulfo-NHS-LC-Biotin Kit, Pierce/Thermo Scientific). Biotinylation 
was verified by gel-shift with streptavidin by SDS–PAGE. 
Binding of scTv proteins measured by surface plasmon resonance 
The binding of purified refolded scTv proteins to cognate peptide-HLA.A2 was monitored with 
surface plasmon resonance (SPR) using a Biacore 3000 instrument. Complexes of the Tax11–19 
and SL977–85 peptides with HLA-A*02:01 (called HLA.A2 hereafter) were generated by 
refolding from bacterially expressed heavy chain and β2m inclusion bodies as previously 
described (Davis-Harrison et al., 2005). Due to the high affinities of the scTv proteins, a kinetic 
titration assay was utilized, in which increasing concentrations of analyte were sequentially 
injected over the surface without the requirement for disruptive regeneration injections (Karlsson 
et al., 2006). Experiments were performed with 868-Z11 and A6-X15 amine coupled to a 
standard CM5 sensor chip. Peptide/MHC analyte was sequentially injected at various 
concentrations. The amount of immobilized scTv was kept below 500 RU and the flow rate was 
set to the maximum of 100 μl/min to minimize mass transport effects. Data were analyzed using 
Biaevaluation 4.1 as described (Karlsson et al., 2006). Solution conditions were 10 mM HEPES 
(pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P-20, 25°C. 
Binding of scTv proteins to peptide-loaded antigen-presenting cells 
To examine binding of soluble scTv protein to peptide presented by HLA.A2 on cells, T2 cells 
(HLA-A*02:01+) were incubated for 2 h with various concentrations of peptides. Cells were then 
washed twice with 0.5% PBS/BSA, and incubated at room temperature for 30 min with 
biotinylated scTv at various concentrations. Cells were washed twice with 0.5% PBS/BSA, 
followed by incubation with SA:PE for 30 min at room temperature. Cells were washed twice 
and analyzed using an Accuri C6 Flow Cytometer. 
 
Results 
Yeast display of human scTvs 
To determine whether human TCRs could be expressed in single-chain formats, we cloned three 
human TCRs (Fig. 1) that had high affinity for their respective pep-HLA.A2 ligands, thus 
allowing the pepMHC to be used as high-affinity probes for properly folded and associated 
VαVβ binding sites. The TCRs were engineered previously for higher affinity, using a full-length 
TCR format and phage display (Li et al., 2005; Sami et al., 2007; Varela-Rohena et al., 2008). 
The variable domains contained various mutations in the CDRs that conferred high affinity, and 
they were fused by a linker peptide (L) in the orientation Vβ–L–Vα (Supplementary data, Fig. 
S1). The single-chain constructs were cloned at the C-terminus of the yeast cell wall protein 
Aga2, followed by a hemagglutinin (HA) peptide tag for detection of displayed proteins. 
Yeast cells containing the 1G4, A6 and 868 scTv fusions were induced, and the cells were 
stained with an anti-HA antibody (Fig. 1B). All three constructs showed high levels of 
expression of the HA tag, as evidenced by a positive population (the negative population has 
been found in all yeast displayed systems, and is due to a fraction of yeast cells that lose the 
plasmid during induction). To detect properly folded VαVβ domains, the respective peptide/A2 
tetramers were used for staining the same induced yeast cells. As expected, based on previous 
studies with various scTv fragments (Richman et al., 2009), neither the 1G4 nor A6 scTv were 
positive with their respective cognate pep/HLA.A2 ligands (Fig. 1B), consistent with the absence 
of properly folded scTv proteins on the surface of yeast. Staining of the 1G4 and A6 cells with 
an antibody to Vβ13 was also negative (unpublished data), confirming that these scTv proteins 
were not expressed on the yeast surface. Surprisingly, the 868 scTv was positive for staining 
with its cognate ligand, SL9/HLA.A2, even at the concentration of 10 nM (Fig. 1B). This 
represented the first time that an scTv fragment could be detected as a properly folded protein, 
without the need for random mutation and selection (Kieke et al., 1999; Weber et al., 2005; 
Richman et al., 2009). 
Engineering of stabilized surface displayed scTv fragments by random 
mutagenesis 
Although the features of the 868 V regions that allowed display were unknown, this TCR uses a 
Vβ (Vβ5) that differs from 1G4 (Vβ13) and A6 (Vβ13), while it uses a Vα that is similar to A6 
(Vα2). This may imply that the Vβ5 region of 868 confers stability on the protein. To gain 
insight into the mechanisms that enable scTv stability and surface display, we performed 
mutagenesis and selections for displayed proteins. First, to determine if the 1G4 and A6 scTv 
could be stabilized by specific V-region mutations, the scTv genes were subjected to rounds of 
random mutagenesis and libraries were sorted with pep/HLA.A2 tetramers to isolate scTv 
mutants with improved surface expression. Despite multiple efforts, through various rounds of 
mutagenesis and sorting with NYESO/HLA.A2 tetramers, yeast displayed 1G4 scTv could not 
be isolated (data not shown). 
In contrast, stabilized mutants of the A6 scTv were isolated after mutagenesis and sorting with 
the Tax/HLA.A2 tetramers (100 nM) (data not shown). Previous experiments with the mouse 
TCRs 2C and 3.L2 demonstrated that selection of scTv fragments with increased resistance to 
thermal denaturation yielded mutants with significantly higher levels of display that correlated 
with soluble secretion efficiency (Shusta et al., 2000; Weber et al., 2005). Consequently, the A6 
scTv library was sorted with Tax/HLA.A2 tetramer after incubation at a higher temperature 
(42°C) and several mutants, including a clone called A6-X15 with improved yeast surface levels, 
were isolated (Fig. 2). The scTv mutant A6-X15 (mean fluorescence intensity MFI = 1600, 
sequence provided in Supplementary data, Fig. S1) was expressed at higher surface levels than 
the A6 template scTv (MFI = 50) or the full-length TCR (MFI = 200) (Fig. 2), with stabilized C 
region cysteines, as monitored by Tax/HLA.A2 tetramer. In the full-length A6 TCR, each of the 
Cα and Cβ antibodies detected higher surface levels than tetramer, suggesting that the fully 
folded and assembled dimer represents only a subset of the total α and β chains on the surface. 
Notably, introduction of the Vβ mutations from A6-X15 into the 1G4 scTv, which shares Vβ 




Fig. 2  Isolation of stabilized A6 scTv mutants and yeast display of with full-length A6 TCR. (A) 
The high-affinity A6 TCR was cloned as an scTv, and a library of random mutants was sorted 
with Tax/HLA.A2 tetramer. Clone A6-X15, isolated after two rounds of mutagenesis and 
selection with Tax/A2 tetramer, was stained with anti-HA antibody (left panels, solid gray 
histogram), secondary antibody only (left panels, black line histograms), 100 nM Tax/A2 
tetramer (right panels, solid black histogram) or 100 nM null peptide NYESO/A2 tetramer (right 
panels, gray line histogram). (B) The full-length A6 TCR with β chain expressed as a fusion to 
AGA-2 and α chain secreted was used to compare full-length and single-chain formats. Surface 
expression of α and β chains was monitored with anti-Cα or anti-Cβ antibody (left panels, black 
line histograms) or with goat anti-mouse IgG secondary antibody only as a control (left panels, 
gray line histograms). Cells were stained with 100 nM Tax/A2 tetramer (right panel, solid black 
histogram) or 100 nM null peptide NYESO/A2 tetramer (right panel, gray line histogram). Mean 
fluorescence units of positive peaks are shown. 
 
Based on our previous results (Shusta et al., 2000; Weber et al., 2005), we also sought to identify 
mutants of the 868 scTv that would exhibit increased stability. The 868 scTv gene was randomly 
mutagenized by error-prone PCR, and the library was subjected to several rounds of sorting with 
SL9/HLA.A2 tetramer, including a round after incubation at 40°C. Various temperature stable 
clones were isolated, including a mutant called 868-Z11 that bound to SL9/HLA.A2 tetramer at 
concentrations as low as 1 nM as detected by flow cytometry (Fig. 3 and data not shown, 
sequence provided in Supplementary data, Fig. S1). Clone 868-Z11 exhibited improved surface 
levels that were almost 10-fold improved relative to the 868 scTv template (Fig. 3). In addition, 
like the A6 TCR, the scTv forms of the 868 TCR were also detected at higher levels than the 
full-length format that contained C regions with the stabilizing cysteines (Fig. 3). This 
demonstrated that the single-chain format allows for much higher surface levels of productively 
associated Vα:Vβ pairs relative to the full-length display format. This is consistent with a 
previous finding using the mouse 2C system, comparing the temperature-stabilized scTv and 






Fig. 3  Isolation of stabilized 868 scTv mutants and yeast display of scTv and full-length 868 
TCR. (A) The high-affinity 868 TCR was cloned as an scTv, and a library of random mutants 
was sorted with HIV Gag SL9/HLA.A2 (SL9/A2). Clone 868-Z11, isolated after one round of 
mutagenesis and selection with SL9/A2 tetramer, was stained with anti-HA antibody (left panels, 
solid gray histogram), secondary antibody only (left panels, black line histograms), 10 nM 
SL9/A2 tetramer (right panels, solid black histogram) or 10 nM null peptide NYESO/A2 
tetramer (right panels, gray line histogram). (B) The full-length 868 TCR with β chain expressed 
as a fusion to AGA-2 and α chain secreted was used to compare full-length and single-chain 
formats. Surface expression of α and β chains was monitored with anti-Cα or anti-Cβ antibody 
(left panels, black line histograms) or with goat anti-mouse IgG secondary antibody only as a 
control (left panels, gray line histograms). Cells were stained with 10 nM SL9/A2 tetramer (right 
panels, solid black histogram) or 10 nM null peptide NYESO/A2 tetramer (right panels, gray line 
histogram). Note that the 868-Z11 scTv staining with tetramer is shown again, as in this 
experiment different flow cytometry settings were used compared to (A), resulting in the 
indicated mean fluorescence units for comparison with full-length 868 TCR. 
 
To examine what mutations in the A6 and 868 scTv conferred enhanced yeast surface levels and 
temperature stability, various clones, including A6-X15 and 868-Z11, were sequenced (Fig. 4). 
The A6-X15 clone showed only mutations in the Vβ13 region, with no mutations in the Vα2. 
Several of these Vβ mutations (A52V, N63D, N66K, Q106L) were also shared with the 
stabilized clone A6-X3 (Fig. 4A). Thus, it appeared that in A6, the wild-type Vα2 region, but not 
the Vβ13 region, was sufficiently stable to allow its expression, proper folding and assembly 





Fig. 4  Sequences of selected A6 and 868 scTv mutants showing highest surface levels following 
thermal denaturation. Mutants of the A6 scTv (A) or the 868 scTv (B) were isolated after 
mutagenesis of the scTv genes, followed by surface expression, high-temperature exposure and 
selection with tetramers. Sequences are coded as follows: yellow, high-affinity CDR mutations 
for A6 (Li et al., 2005) and for 868 (Varela-Rohena et al., 2008); red, conserved 
immunoglobulin fold residues, black-boxed residues, mutations identified in selected mutants. 
Note: for ease of comparing with published structures, residues of each variable domain of the 
scTv are numbered sequentially, and thus do not correspond to IMGT nomenclature. 
 
In contrast to the A6 scTv mutants, the stabilized 868 scTv clones did not show any shared 
mutations in the Vβ region, but they contained a single shared mutation in the Vα2 region, 
F49αS (Fig. 4B). (Note that the numbering follows that used in the pdb file of A6; based on 
IMGT sequences, this residue is numbered 55.) Interestingly, the Ser49 residue is also found in 
the Vα2 of the A6 TCR, and represents a polymorphism at this position (Supplementary data, 
Fig. S2). 
Polymorphic residue 49 of Vα2 influences Vα and Vβ domain stability 
As indicated, the sequences of the five most stable 868 scTv clones (out of 20) isolated after 
temperature stability sorting shared a single Vα mutation, PheVα49Ser, and this was the only Vα 
mutation present in the most stable 868 clone, 868-Z11 (Fig. 4B). To assess whether this 
mutation alone, and not the Vβ mutations, was responsible for the enhanced stability of the 868-
Z11 mutant, the PheVα49Ser mutation was introduced into the 868 scTv. Staining of this mutant 
after incubation at 40°C showed that this single mutation provided the protein with improved 
resistance to thermal denaturation, resulting in over a 10-fold increase in the surface level 




Fig. 5  Residue 49 of the Vα2 region influences thermal stability of the 868 scTv. The serine 
polymorphism/mutation at position 49 was introduced into the 868 scTv template. Yeast cells 
were incubated at room temperature (top row) or at 40°C for 30 min and then stained with 10 nM 
SL9/A2 SA:PE tetramer (black line histograms) or null peptide Tax/A2 SA:PE tetramer (gray 




Relative effects of CDR and Serα49 mutations on yeast display of scTv 
Our previous work with the mouse TCRs 2C and 3.L2 has shown that some CDR mutations can 
also confer increased stability to the scTv format (Kieke et al., 1999; Weber et al., 2005). It is 
possible that the 868 CDR mutations that were selected for higher affinity binding to 
SL9/HLA.A2 also contributed to stability of the scTv format. Accordingly, the wild-type CDR 
residues were cloned into the 868 scTv format (WT), with either a Pheα49 or Serα49 residue. To 
approach this question, we could not use the tetramer for detection, due to the low affinity of the 
wild-type TCR. Thus, an antibody to the TCR Vβ5 domain was used as a surrogate to assess 
surface levels (Fig. 6). The WT 868 scTv with the Serα49 residue showed significantly improved 
surface levels, relative to the WT 868 scTv with the Pheα49 residue, which was barely detectable 
with the anti-Vβ5 antibody. Although the Serα49 residue yielded enhanced surface levels with the 
high-affinity mutations (MUT) in the CDRs, in this case even the scTv with the Pheα49 residue 
was easily detected with the anti-Vβ5 antibody (Fig. 6). Thus, the CDR mutations that yielded 
higher affinity also contributed to enhanced stability. We have observed a reciprocal selection 
scenario, in which stabilizing mutations in the CDR1α of an scTv also yielded higher affinity 





Fig. 6  CDR mutations and the PheVα49Ser mutation each improve the surface display of the 868 
scTv. Various 868 scTv proteins were expressed in the yeast display system with wild-type CDR 
residues or with high-affinity CDR mutations (Fig. 4B), with either Phe or Ser at position α49. 
Top row, cells stained with anti-Vβ5.2 antibody and goat anti-mouse (black line histograms) or 
secondary antibody only (gray-lined histograms). Bottom row, surface expression was also 
monitored with SL9/A2 tetramers (black line histograms) or null peptide Tax/A2 tetramers 
(gray-lined histograms). Mean fluorescence units of positive peaks are shown (or in cases where 
only a negative peak is present, the mean of this peak). 
 
To further investigate whether the high-affinity mutations in the CDR2β and/or the CDR3α were 
responsible for the enhanced surface stability, the wild-type CDR2β and CDR3α sequences were 
individually introduced into the template high-affinity 868 scTv, with the Pheα49 or Serα49 
residue, and yeast surface levels were monitored by staining with anti-Vβ5 antibody. The high-
affinity mutations in CDR3α conferred improved Vβ surface levels as monitored with the anti-
Vβ5 antibody, in comparison to the WT scTv with Pheα49 (Fig. 6). In contrast, the high-affinity 
mutations in CDR2β did not increase substantially the Vβ surface levels in the presence of Pheα49 
but appeared to act synergistically in the presence of Serα49. Thus, it appears that both CDR 
mutations and the Serα49 mutation provided enhanced stability to the scTv format of this TCR. 
The maximal scTv surface levels observed for binding of SL9/HLA.A2 tetramers to proteins that 
contained the high-affinity mutations (Fig. 6) also substantiated these findings. 
Expression of soluble human scTv proteins in E.coli, and peptide:HLA.A2 
binding 
Our previous studies with mouse TCRs 2C and 3.L2 have shown that the generation of yeast 
surface displayed mutants of the scTv proteins allowed the mutants to be expressed in E.coli in 
both secreted form and refolded from inclusion bodies (Weber et al., 2005; Jones et al., 2006 , 
2008). To determine if this were possible with the human scTv mutants, the A6-X15 and 868-
Z11 scTv genes were cloned into an E.coli expression vector and the induced E.coli cells 
expressed the expected size proteins (data not shown). The scTv proteins were refolded from 
inclusion bodies with yields of >1 mg/l of culture, yielding purified scTv proteins of the expected 





Fig. 7  Expression, purification and SPR binding studies of soluble scTv proteins A6-X15 and 
868-Z11. A6 clone X15 and 868 clone Z11 were expressed in the E.coli pET28 expression 
system. Proteins were refolded from inclusion bodies, and purified by Ni-column and size 
exclusion chromatography. (A) SDS–PAGE of purified A6-X15 and 868-Z11 scTv proteins, and 
indicated molecular weight markers (M). (B) SPR traces of Tax/A2 binding immobilized A6-
X15. Concentrations of injected pepMHC analyte are indicated below each injection. Black line 
represents a fit to a 1:1 binding interaction using a kinetic titration scheme as described in the 
Materials and methods section. Fitted parameters (KD, kon, koff) are shown in the inset. (C) SPR 
traces of SL9/A2 binding immobilized 868-Z11. 
 
Two different binding studies were conducted. First, SPR was performed with purified 
peptide/HLA.A2 binding immobilized scTv to determine solution binding affinities and kinetics. 
A kinetic titration experiment was performed, obviating the need for potentially destabilizing 
regeneration steps necessary when high-affinity interactions are studied with SPR (Karlsson et 
al., 2006). Analysis of the data for the A6-X15-Tax/HLA.A2 and 868-Z11-SL9/HLA.A2 
interactions yielded nanomolar and picomolar binding affinities for the A6-X15 and 868-Z11 
interactions, respectively (Fig. 7B and C). The relative values correlated with the affinities seen 
with the full-length proteins and confirmed the single-chain constructs retained specificity and 
high affinity for their cognate ligand. Any differences with the previously published affinities (Li 
et al., 2005; Varela-Rohena et al., 2008; Piepenbrink et al., 2009) may reflect difficulties 
quantifying high-affinity binding via SPR, or possibly an influence of the mutations generated 
via yeast display, or the linker, on binding affinity. These possibilities are currently being 
investigated. 
In a second approach, we determined whether cell surface pep/HLA.A2 complexes could be 
detected with soluble scTv protein. The 868 scTv protein was biotinylated using a biotin-
succinimidyl cross-linking agent that reacts with free amines (the 868 scTCR linker contains 
multiple lysines, whereas the scTv contains no lysines in the CDR loops). The HLA.A2-positive 
human cell line T2 was loaded with SL9 peptide or Tax (868-null) peptide at 10 μM and cells 
were subsequently incubated with various concentrations of biotinylated-868-Z11 scTv followed 
by streptavidin:PE at room temperature (Fig. 8A). Soluble 868-Z11 scTv detected SL9 peptide 
loaded cells at scTv concentrations below 1nM, whereas cells loaded with the null peptide Tax 
were not positive even at the highest concentration of 868-Z11 scTv (Fig. 8A). The concentration 
that yielded 50% maximal staining, an estimate of the KD of the reaction, was ∼4 nM scTv 
(Fig. 8B). This approach, using flow cytometry, has provided affinity estimates that are in good 
agreement with values derived using SPR and soluble proteins, in the KD range of ∼1–200 nM 




Fig. 8  Recognition of peptide-loaded antigen-presenting cells with soluble 868-Z11 scTv. (A) 
Titration of various concentrations of the biotinylated 868 scTv on antigen-presenting cell line 
T2 (HLA.A2+) pre-loaded with SL9 (10 μM) peptide, or null peptide Tax (10 μM). Cells were 
stained at room temperature for 30 min with scTv, washed, and stained with SA:PE for 30 min. 
Analysis was performed after two additional washes. (B) Mean fluorescence intensity (MFI) 
values of scTv titration shown in (A) were plotted versus scTv concentration, to determine the 
concentration that yielded 50% maximal binding, EC50, for 868 Z11 scTv. (C) The SL9 peptide 
was titrated on T2 cells, and subsequently stained with a saturating concentration (100 nM) of 
biotinylated 868-Z11 scTv. 
 
To examine the peptide sensitivity of binding by the scTv, the SL9 peptide was titrated on T2 
cells and the antigen-presenting cells were stained with biotinylated 868-Z11 scTv at 100 nM 
(Fig. 8C). Without any optimization of staining signal, the scTv detected the peptide at 
concentrations as low as 10 nM. It remains to be seen how this concentration corresponds to 
levels associated with endogenous processing and presentation of the SL9 peptide. Nevertheless, 
the scTv fragments appear to be quite stable, as even after storage at 4°C for over 1 year, the 
protein was able to bind target cells loaded with low nanomolar peptide concentrations (data not 
shown). Thus, they should be useful in addressing the challenges that remain with targeting of 
the natural HIV epitope, or other pepMHC, which are presented at relatively low levels 
compared with most current antibody-targeted antigens (Richman and Kranz, 2007). 
 
Discussion 
It has been known for many years that the expression and crystallization of the extracellular 
region of αβ TCRs have posed significant problems, when compared with either antibodies or 
MHC proteins (reviewed in Rudolph et al., 2006). The explanation for this difficulty lies, at least 
in part, in the behavior of TCR variable regions. This also accounts for problems that have 
plagued efforts to use scTv V-region fragments in the same way that has been done with 
antibody single-chain Fv fragments (Richman et al., 2009). Here, we show that it is possible to at 
least in part overcome these inherent problems by using a specific human V-region family, Vα2 
(IMGT: TRAV12 family). This Vα region appears to be over-represented among human T cells 
directed against a number of HLA.A2-associated antigenic peptides, perhaps most notably 
peptides from MART1/MelanA (ELAGIGILTV) and Epstein Barr Virus protein BMLF1 
(GLCTLVAML) (Mantovani et al., 2002; Trautmann et al., 2002; Dietrich et al., 2003). It is 
possible that the inherent stability of Vα2, observed in the context of scTv proteins described 
here, might contribute to its preferential use in some T cell responses, and in the original 
isolation of the HTLV-1 Tax and HIV-1 Gag-specific TCRs, A6 and 868 (Utz et al., 1996; 
Varela-Rohena et al., 2008). 
In previous studies, we have attempted to provide a possible molecular rationale for V-region 
mutations that enabled the yeast surface display of mouse scTv (Kieke et al., 1999; Shusta et al., 
2000; Weber et al., 2005; Richman et al., 2009) and individual Vβ regions (Buonpane et al., 
2005). The underlying premise was based on our observations that surface display was directly 
correlated with thermal stability of the scTv (Shusta et al., 1999; Orr et al., 2003; Weber et al., 
2005). In some cases, a possible explanation involved enhanced hydrophilicity at positions where 
a residue was buried at the would be V:C interface, or mutations at the Vα:Vβ interface that 
improved domain association. However, a significant number of mutations, such as those present 
within or at the base of CDR loops, have less obvious explanations. For example, it is unknown 
how the CDR3α or CDR2β mutations in the 868 scTv that conferred high affinity also yielded 
enhanced surface display and stability, in the unbound state. In addition, A6 scTv mutants with 
improved stability each contained a mutation within CDR2β, AlaVβ52Val. We have argued that 
some of the CDR mutations could confer local stability on the CDR loops, based on modeling 
predictions (Holler et al., 2003). Similar results with stabilizing CDR mutations in scFv 
fragments have also been observed (Honegger et al., 2009; Miller et al., 2010). 
Additional mutations in the framework 3 region or hypervariable 4 region of the Vβ domains 
may also have contributed to the stability of the A6 and 868 scTv fragments. In the case of A6, 
the AsnVβ62Asp and AsnVβ66Lys mutations within framework 3 were conserved among isolated 
clones. Although the contributions of each individual mutation have not been determined, their 
conservation among 14 out of 20 scTv clones of the A6 TCR (data not shown) suggests that they 
play a role in surface display and stability. 
The mechanism by which residue 49 of the Vα domain confers stability is also not clear. It is 
near the CDR3β (e.g. it is 2.8 Å from Glu105β in A6) loop, such that it is possible that its 
primary role is in stabilization of the Vα:Vβ interface (Fig. 9), a location that has been 
considered important in the design of stabilized scFv fragments (Miller et al., 2010). This area of 
the Vβ (i.e. near Glu105β, which can be encoded by either N-region addition, the D gene, or the 
N-terminus of the Jβ gene) could in turn influence the stabilizing potential of the Vα and Ser49α. 
The residue adjacent to Glu105β, Gln106β, was mutated to Leu in each of the surface displayed 
scTv of A6, suggesting that this region can be further optimized for enhanced stability in the 
context of the Ser49α residue. Furthermore, CDR3α and CDR3β stabilizing mutations (L104αP 
and T105βA) have been identified previously in the mouse 2C scTv (Kieke et al., 1999). Thus, it 
is apparent that various CDR and framework regions can have complex and interdependent 




Fig. 9  Position of the Serα49 residue in the structure of the A6 TCR. V regions of the 
A6:Tax/A2 complex (Garboczi et al., 1996a,b) are shown, highlighting the position of the 
Serα49 residue which is 2.8 Å from CDR3β residue Gluβ105. The Tax peptide (magenta) is 
shown for reference. PDB file 1AO7 was used in PyMol for graphics. 
 
Studies with soluble full-length TCRs (VαCα/VβCβ) have shown that an interchain disulfide 
bond formed by a pair of introduced cysteines in the Cα and Cβ regions can confer additional 
stability on the molecule, enabling expression as a soluble protein (Boulter et al., 2003). This 
form of the TCR has been used for binding studies, and as a platform for affinity engineering (Li 
et al., 2005; Dunn et al., 2006; Varela-Rohena et al., 2008). The design of stable scTv fragments 
that bind to the specific pepMHC ligands, as shown here, provides additional opportunities to use 
the scTv as a platform for various applications, as has been done widely with antibody scFv 
fragments (reviewed in Holliger and Hudson, 2005). These include the use of display 
technologies for affinity engineering (Boder and Wittrup, 2000; Hoogenboom, 2005) and more 
facile production of biophysically well-behaved single-chain proteins in E.coli (Worn and 
Pluckthun, 2001; Ewert et al., 2003). The scTv form also provides a platform for use in chimeric, 
single-chain antigen receptors (reviewed in Sadelain et al., 2009) or in soluble form as bispecific 
fusions that could include, anti-CD3 antibodies, toxins or cytokines (Bargou et al., 2008; Miller 
et al., 2010). As we have discussed in a previous review (Richman and Kranz, 2007), the most 
significant challenge with the use of soluble TCRs, whether single-chain or full-length forms, 
involves the relatively low surface densities associated with processed and presented antigens. 
Based on the diverse sequences of the HLA.A2-restricted peptides that have elicited Vα2+ T cells 
(e.g. MART1, ELAGIGILTV; EBV, GLCTLVAML; Tax, LLFGYPVYV; Gag, SLYNTVATL), 
we anticipate that it should be possible to generate Vα2+ scTv proteins against a wide array of 
diverse antigens. Two structures are available for Vα2+ TCRs in complex with pep-HLA.2, the 
A6 TCR:Tax/A2 complex (Garboczi et al., 1996a,b) and the MEL5 TCR/MART-1/A2 complex 
(Cole et al., 2009). The two TCRs dock in almost identical orientations on their pep-A2 ligands, 
and they share CDR1α interactions with both the α2 helix and peptide positions 1 and 4. Peptide 
specificity appears to be achieved in large part through interactions with CDR3β, providing 
support to the notion that the scTv proteins described here, which use distinct Vβ regions, can 
maintain their antigen specificity through the involvement of other CDRs. 
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